Shelley Chu has more than two decades of venture investing and operating experience in the biopharmaceutical industry. Her passion is working closely with entrepreneurs to navigate scientific, clinical, regulatory, business development, and commercial hurdles to bring innovative new medicines to market that address significant unmet medical needs. At Lightspeed, Shelley leads the firm’s biotech investments from seed (including research from UCSF, Stanford, Scripps, MIT, and Harvard) to late stage. To date, her investments across all stages have yielded 7 New Drug Approvals by the FDA, 10 drug candidates in ongoing clinical development, and 17 exits through mergers and acquisi6ons, IPOs or partnerships. Shelley has also led R&D strategy at Gilead across all therapeutic areas and business development in immuno-oncology and HBV. Shelley holds an M.D. and a Ph.D. in biochemistry and biophysics from the University of California at San Francisco (UCSF) and a B.A. in molecular biology from Princeton University, where she is a co-chair for Princeton ASC.